NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I disagree. My opinions are merely my opinions, and NWBO still needs to update us, imho. If you think about it, the Avastin decision happened a few days after the latest financing, and if I'm correct, it might mean no more financings are necessary for NWBO prior to topline if they have data sufficient for PFS approval. Look, there is likely no one left to cross-over to DCVax-L from placebo (aka: likely all placebo already PFS evented), imho, or less than a handful are left to event. They just can't confound this trial via immediate crossover if PFS is already significant. imho. If there is someone left to crossover to DCVax-L, they now have a higher ethical obligation to do so if PFS was significant, because now PFS is a fully approvable endpoint for GBM. They can't mess up OS data for reimbursement imho, because if they prefer, they could wait to report the highest OS later for reimbursement -- again, immediate crossover to DCVax-L can't hurt OS integrity at this point if PFS was significant. imho. Remember, as Senti pointed out, the NICE pricing decisions typically occur after regulator approval. Again, if PFS is statistically significant. IMHO.